<DOC>
	<DOCNO>NCT02827578</DOCNO>
	<brief_summary>Efficacy Safety Tamsulosin/Solifenacin Combination therapy Patients void symptom moderate severe storage symptom due Benign Prostate Hyperplasia : randomize , double blind , parallel design , active control , multi-center , phase 3 clinical trial</brief_summary>
	<brief_title>Efficacy Safety Tamsulosin/Solifenacin Combination Therapy Patients With Voiding Symptoms Moderate Severe Storage Symptoms Due Benign Prostate Hyperplasia</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>1 . Healthy male age 45 year old old 2 . Subjects benign prostatic hyperplasia diagnose digital rectal examination 3 . Subjects low urinary tract symptom suggestive benign prostate hyperplasia , spontaneously agree join sign consent form 1 . Subjects history low urinary tract cancer , include prostate cancer bladder cancer within past 5 year 2 . Subjects acute urinary retention within 4 week screen 3 . Subjects clinically significant severe cardiovascular disease ( unstable angina , myocardial infarction arrhythmia ) within 6 month screen 4 . Subjects hypersensitivity investigational product sulfa medication 5 . Subjects suspect confirmed calculus lower urinary tract , calculus bladder ( except complete recovery , ) 6 . Subjects myasthenia gravis , narrow angle glaucoma autonomic neuropathy 7 . Subjects cataract glaucoma schedule operate study duration . 8 . Subjects hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption 9 . Subjects judge investigator unsuitable participate clinical trial .</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>